Avadel Pharmaceuticals (AVDL) Debt to Equity: 2009-2022
Historic Debt to Equity for Avadel Pharmaceuticals (AVDL) over the last 12 years, with Sep 2022 value amounting to -$10.95.
- Avadel Pharmaceuticals' Debt to Equity fell 862.71% to -$10.95 in Q3 2022 from the same period last year, while for Sep 2022 it was -$10.95, marking a year-over-year decrease of 862.71%. This contributed to the annual value of $1.82 for FY2021, which is 130.33% up from last year.
- Avadel Pharmaceuticals' Debt to Equity amounted to -$10.95 in Q3 2022, which was up 72.83% from -$40.31 recorded in Q2 2022.
- Avadel Pharmaceuticals' Debt to Equity's 5-year high stood at $45.03 during Q4 2018, with a 5-year trough of -$40.31 in Q2 2022.
- Moreover, its 3-year median value for Debt to Equity was $0.79 (2020), whereas its average is -$3.74.
- In the last 5 years, Avadel Pharmaceuticals' Debt to Equity soared by 11,247.90% in 2021 and then plummeted by 3,480.12% in 2022.
- Over the past 5 years, Avadel Pharmaceuticals' Debt to Equity (Quarterly) stood at $45.03 in 2018, then tumbled by 109.68% to -$4.36 in 2019, then spiked by 118.13% to $0.79 in 2020, then surged by 130.33% to $1.82 in 2021, then tumbled by 862.71% to -$10.95 in 2022.
- Its Debt to Equity was -$10.95 in Q3 2022, compared to -$40.31 in Q2 2022 and $2.58 in Q1 2022.